Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)
China flag China · Delayed Price · Currency is CNY
4.210
-0.070 (-1.64%)
May 20, 2026, 11:29 AM CST

SHA:600572 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
6,6036,3826,4266,6525,9456,531
Other Revenue
91.4391.4389.0280.5954.9537.67
6,6946,4736,5156,7336,0006,568
Revenue Growth (YoY)
4.99%-0.64%-3.23%12.21%-8.64%11.15%
Cost of Revenue
3,1143,0513,1012,8352,4702,626
Gross Profit
3,5803,4223,4143,8973,5313,942
Selling, General & Admin
2,6452,5642,4802,8322,5812,964
Research & Development
259.39262.22300.02298.09195.72202.49
Other Operating Expenses
84.7465.4352.8-38.4962.9964.65
Operating Expenses
2,9882,8932,8343,0932,8403,268
Operating Income
591.72529.22580.51804.32690.41674.18
Interest Expense
-6.96-7.79-20.79-36.4-49.47-73.22
Interest & Investment Income
95.8895.48101.92135.2789.352,611
Currency Exchange Gain (Loss)
-1.75-1.755.223.09-1.110.06
Other Non Operating Income (Expenses)
-12.09-11.16-1.65-21.98-3.76-9.31
EBT Excluding Unusual Items
660.25604665.22884.3725.423,203
Gain (Loss) on Sale of Investments
-13.0925.6430.27-146.04-238.23-714.69
Gain (Loss) on Sale of Assets
4.874.8916.9135.6836.0242.22
Asset Writedown
-31.8-26.81-1.82-7.18-1.84-95.71
Other Unusual Items
49.0437.4569.360.9368.6492.55
Pretax Income
669.27645.17779.94767.69590.012,527
Income Tax Expense
167.71153.62121.5992.97129.89391.13
Earnings From Continuing Operations
501.56491.55658.35674.72460.122,136
Minority Interest in Earnings
-18.14-17.19-35.94-83.15-102-118.31
Net Income
483.42474.36622.42591.57358.122,017
Net Income to Common
483.42474.36622.42591.57358.122,017
Net Income Growth
-18.86%-23.79%5.21%65.19%-82.25%345.06%
Shares Outstanding (Basic)
2,5012,4972,4902,5722,5582,586
Shares Outstanding (Diluted)
2,5012,4972,4902,5722,5582,586
Shares Change (YoY)
-3.29%0.28%-3.20%0.55%-1.10%2.71%
EPS (Basic)
0.190.190.250.230.140.78
EPS (Diluted)
0.190.190.250.230.140.78
EPS Growth
-16.10%-24.00%8.70%64.29%-82.05%333.33%
Free Cash Flow
878.62795.35721.9689.5863.73309.8
Free Cash Flow Per Share
0.350.320.290.270.340.12
Dividend Per Share
0.1500.1500.1500.2000.1500.160
Dividend Growth
---25.00%33.33%-6.25%-
Gross Margin
53.48%52.87%52.41%57.88%58.84%60.02%
Operating Margin
8.84%8.18%8.91%11.95%11.51%10.26%
Profit Margin
7.22%7.33%9.55%8.79%5.97%30.72%
Free Cash Flow Margin
13.13%12.29%11.08%10.24%14.39%4.72%
EBITDA
921.45861.21921.471,129963.34956.65
EBITDA Margin
13.76%13.30%14.14%16.76%16.05%14.56%
D&A For EBITDA
329.74331.98340.96324.35272.93282.47
EBIT
591.72529.22580.51804.32690.41674.18
EBIT Margin
8.84%8.18%8.91%11.95%11.51%10.26%
Effective Tax Rate
25.06%23.81%15.59%12.11%22.02%15.48%
Revenue as Reported
6,6946,4736,5156,7336,0006,568
Source: S&P Global Market Intelligence. Standard template. Financial Sources.